|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2001
Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD
1 Section of Pulmonary and Critical Care Medicine, Dept of Medicine, Dartmouth Medical School, Lebanon. 2 National Institute of Respiratory Disease, Mexico City, Mexico
CORRESPONDENCE: D.A. Mahler, Pulmonary & Critical Care Medicine, 3-D, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756-000. Fax: 961 6036504437
Keywords: bronchodilator therapy, dyspnoea ratings, inspiratory capacity
Received: October 12, 2000
Accepted February 12, 2001
Study was supported by a grant from GlaxoWellcome Inc.
The hypothesis of the study was that salmeterol and ipratropium would have similar dyspnoea ratings during steady-state cycle ergometry at 1 h, but that salmeterol would reduce dyspnoea at 6 h after administration in patients with chronic obstructive pulmonary disease (COPD).
The study design was a randomized, double-blind trial in 16 patients (aged 63±11 yrs) with symptomatic COPD. Two days after familiarization with testing procedures, patients were randomly assigned to receive either two puffs (42 µg) of salmeterol and two puffs of placebo inhaler, or two puffs (36 µg) of ipratropium from each of two inhalers (total, 72 µg). Two days later, patients received the alternative medication. During exercise at 60% of peak oxygen consumption patients rated dyspnoea and performed inspiratory capacity manoeuvres each minute.
Forced expiratory volume in one second was 1.13±0.48 L (37±13% predicted). Dyspnoea ratings were similar for salmeterol and ipratropium at 1 and 6 h. Inspiratory capacity was similar for salmeterol and ipratropium at 1 h, but significantly higher for salmeterol at 6 h (
It is concluded that with the doses used, salmeterol and ipratropium provided similar dyspnoea ratings during exercise at 1 and 6 h after administration.
=120 mL; p=0.03).
This article has been cited by other articles:
|
|
 |
|
  D E O'Donnell, P Laveneziana, J Ora, K A Webb, Y-M Lam, and D Ofir Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD Thorax, March 1, 2009; 64(3): 216 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur. Respir. J., February 1, 2008; 31(2): 416 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. Hanania and J. F. Donohue Pharmacologic Interventions in Chronic Obstructive Pulmonary Disease: Bronchodilators Proceedings of the ATS, October 1, 2007; 4(7): 526 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Palange, S. A. Ward, K-H. Carlsen, R. Casaburi, C. G. Gallagher, R. Gosselink, D. E. O'Donnell, L. Puente-Maestu, A. M. Schols, S. Singh, et al. Recommendations on the use of exercise testing in clinical practice Eur. Respir. J., January 1, 2007; 29(1): 185 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. O'Donnell, F. Sciurba, B. Celli, D. A. Mahler, K. A. Webb, C. J. Kalberg, and K. Knobil Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD. Chest, September 1, 2006; 130(3): 647 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Scano, L. Stendardi, and M. Grazzini Understanding dyspnoea by its language Eur. Respir. J., February 1, 2005; 25(2): 380 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.E. O'Donnell, N. Voduc, M. Fitzpatrick, and K.A. Webb Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease Eur. Respir. J., July 1, 2004; 24(1): 86 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A Dougherty, B. L Didur, and L. S Aboussouan Long-Acting Inhaled {beta}2-Agonists for Stable COPD Ann. Pharmacother., September 1, 2003; 37(9): 1247 - 1255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Di Marco, J. Milic-Emili, B. Boveri, P. Carlucci, P. Santus, F. Casanova, M. Cazzola, and S. Centanni Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD Eur. Respir. J., January 1, 2003; 21(1): 86 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Mahler, P. Wire, D. Horstman, C.-N. Chang, J. Yates, T. Fischer, and T. Shah Effectiveness of Fluticasone Propionate and Salmeterol Combination Delivered via the Diskus Device in the Treatment of Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., October 15, 2002; 166(8): 1084 - 1091. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |